Phase I Study of LJM716 in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer
by on Monday, May 21st, 2012 | No Comments
Condition: Advanced HER2-positive Breast Cancer
Interventions: Drug: LJM716; Drug: Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified May 2012
Follow this link: Phase I Study of LJM716 in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer